Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Impatients N.V. trading as myTomorrows
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2023
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Impatients N.V. trading as myTomorrows
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pritelivir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Thorough QT/QTc of Pritelivir in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 04, 2023
Lead Product(s) : Pritelivir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2022
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : AiCuris
Deal Size : Undisclosed
Deal Type : Collaboration
AiCuris collaborates with myTomorrows
Details : The companies are collaborating to develop an Early Access Program for pritelivir, for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 02, 2020
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : AiCuris
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Receiving Breakthrough Therapy Designation will facilitate AiCuris goal of bringing pritelivir to patients as quickly as possible . Company is now preparing to add a pivotal Phase 3 trial part to the ongoing Phase 2 study in immunocompromised patients.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2020
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Medpace, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2017
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Medpace, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Novella Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2016
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Novella Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Medpace, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 07, 2012
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Medpace, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : FHI 360
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2010
Lead Product(s) : Pritelivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : FHI 360
Deal Size : Inapplicable
Deal Type : Inapplicable